NEW YORK (GenomeWeb) – Time-to-next treatment can act as a surrogate endpoint to predict cancer patient outcomes and help establish the clinical utility of tests that match tumor biomarkers to drugs, according to a Caris Life Sciences study.
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.